Vimarsana
Biggest News Aggregation in the World

Page 41 - Contracting Command News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Contracting Command. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Contracting Command Today - Breaking & Trending Today

Lockheed Martin Wins $84.5M Contract for Kuwait Ground Based Radar Systems - Vimarsana News

Lockheed Martin Wins $84.5M Contract for Kuwait Ground Based Radar Systems

Lockheed Martin, Liverpool, New York, has been awarded an $84.5 million contract for the Kuwait Ground Based Radar Systems.

IMT Defense Corporation Wins $391M Contract to Provide Army with Artillery Projectile Parts - Vimarsana News

IMT Defense Corporation Wins $391M Contract to Provide Army with Artillery Projectile Parts

IMT Defense Corporation, Westerville, Ohio, wins a $391 million contract to provide 155 mm artillery M795 projectile metal parts.

TPT Global Tech, Inc.: TPT Global Tech Subsidiary Awarded $2.86 Million U.S. Army Contract - Vimarsana News

TPT Global Tech, Inc.: TPT Global Tech Subsidiary Awarded $2.86 Million U.S. Army Contract

TPT Strategic subsidiary wins its third Army logistics contract for Fort Hood Texas with more similar contracts in its pipelineSAN DIEGO, CA / ACCESSWIRE / November 4, 2022 / TPT Global Tech, Inc. (OTCBB:TPTW)

Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients - Vimarsana News

Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced top-line efficacy and safety...

Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients - Vimarsana News

Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced top-line efficacy and safety results from the FOCUS Phase 3 clinical trial of...